» Articles » PMID: 29373908

Molecular Subtypes of Indonesian Breast Carcinomas - Lack of Association with Patient Age and Tumor Size

Overview
Specialty Oncology
Date 2018 Jan 28
PMID 29373908
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Breast carcinoma (BC) is a heterogeneous disease that exhibits variation in biological behaviour, prognosis and response to therapy. Molecular classification is generally into Luminal A, Luminal B, HER2+ and triple negative/basal-like, depending on receptor characteristics. Clinical factors that determined the BC prognosis are age and tumor size. Since information on molecular subtypes of Indonesian BCs is limited, the present study was conducted, with attention to subtypes in relation to age and tumor size. Methods: A retrospective cross-sectional study of 247 paraffin-embedded samples of invasive BC from Dr. Sardjito General Hospital Yogyakarta in the year 2012- 2015 was performed. Immunohistochemical staining using anti- ER, PR, HER2, Ki-67 and CK 5/6 antibodies was applied to classify molecular subtypes. Associations with age and tumor size were analyzed using the Chi Square Test. Results: The Luminal A was the most common subtype of Indonesian BC (41.3%), followed by triple negative (25.5%), HER2 (19.4%) and luminal B (13.8%). Among the triple negative lesions, the basal-like subtype was more frequent than the non basal-like (58.8 % vs 41.2%). Luminal B accounted for the highest percentage of younger age cases (< 40 years old) while HER2+ was most common in older age (> 50 years old) patients. Triple negative/basal-like were commonly large in size. Age (p = 0.080) and tumor size (p = 0.462) were not significantly associated with molecular subtypes of BC. Conclusion: The most common molecular subtype of Indonesian BC is luminal A, followed by triple-negative, HER2+ and luminal B. The majority of triple-negative lesions are basal-like. There are no association between age and tumor size with molecular subtypes of Indonesian BCs.

Citing Articles

Molecular Subtypes of Breast Cancer in Arab Women: Distribution and Prognostic Insights.

Elkum N, Aboussekhra A, Aboussekhra M, Aldalham H, Alshehri L, Alessy S J Epidemiol Glob Health. 2025; 15(1):36.

PMID: 40063309 PMC: 11893967. DOI: 10.1007/s44197-025-00376-z.


Circulating miR-221/222 expression as microRNA biomarker predicting tamoxifen treatment outcome: a case-control study.

Patellongi I, Amiruddin A, Massi M, Islam A, Pratama M, Sutandyo N Ann Med Surg (Lond). 2023; 85(8):3806-3815.

PMID: 37554919 PMC: 10406100. DOI: 10.1097/MS9.0000000000001061.


Chalcone-3 Inhibits the Proliferation of Human Breast Cancer MDA-MB-231 Cell Line.

Padauleng N, Mustofa M, Wahyuningsih T, Purnomosari D Asian Pac J Cancer Prev. 2023; 24(2):683-691.

PMID: 36853320 PMC: 10162601. DOI: 10.31557/APJCP.2023.24.2.683.


Clinical and X-ray characteristics for expressions of different receptors in patients with breast cancer.

Huang X, Cai S, Wu P, Huang S, Yao M Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021; 46(3):263-271.

PMID: 33927073 PMC: 10929930. DOI: 10.11817/j.issn.1672-7347.2021.190371.


Breast cancer molecular subtypes and receptor status among women at Potchefstroom Hospital: a cross-sectional study.

Kakudji B, Mwila P, Burger J, du Plessis J, Naidu K Pan Afr Med J. 2021; 38:85.

PMID: 33889251 PMC: 8033177. DOI: 10.11604/pamj.2021.38.85.23039.


References
1.
Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S . A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat. 2011; 130(2):489-98. DOI: 10.1007/s10549-011-1709-6. View

2.
Devi C, Tang T, Corbex M . Incidence and risk factors for breast cancer subtypes in three distinct South-East Asian ethnic groups: Chinese, Malay and natives of Sarawak, Malaysia. Int J Cancer. 2012; 131(12):2869-77. DOI: 10.1002/ijc.27527. View

3.
Ly M, Antoine M, Dembele A, Levy P, Rodenas A, Toure B . High incidence of triple-negative tumors in sub-saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. Oncology. 2012; 83(5):257-63. DOI: 10.1159/000341541. View

4.
Liu Y, Xin T, Jiang Q, Huang D, Shen W, Li L . CD147, MMP9 expression and clinical significance of basal-like breast cancer. Med Oncol. 2013; 30(1):366. DOI: 10.1007/s12032-012-0366-x. View

5.
Runnak M, Hazha M, Hemin H, Wasan A, Rekawt R, Michael H . A population-based study of Kurdish breast cancer in northern Iraq: hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data. BMC Womens Health. 2012; 12:16. PMC: 3403969. DOI: 10.1186/1472-6874-12-16. View